ArticleAmerican heart journal2017
An examination of the relationship between serum uric acid level, a clinical history of gout, and cardiovascular outcomes among patients with acute coronary syndrome.
Article in American heart journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Dietary Approaches to Stop Hypertension (DASH) for the primary and secondary prevention of cardiovascular diseases.The Cochrane database of systematic reviews · 2025Pooled it
- Serum uric acid level and prognosis of acute coronary syndrome: a systematic review and dose-response meta-analysis.Frontiers in cardiovascular medicine · 2025Review
- Effect of Ticagrelor versus Clopidogrel on All-Cause and Cardiovascular Mortality in Acute Coronary Syndrome Patients with Hyperuricemia.Clinical drug investigation · 2024Article
- Investigation of the association between serum uric acid levels and HEART risk score in patients with acute coronary syndrome.Physiological reports · 2022Article
- Sex difference in heart failure risk associated with febuxostat and allopurinol in gout patients.Frontiers in cardiovascular medicine · 2022Article
- Serum uric acid is an independent risk factor of worse mid- and long-term outcomes in patients with non-ST-segment elevation acute coronary syndromes.Cardiology journal · 2021Article
- Urate Crystals; Beyond Joints.Frontiers in medicine · 2021Review
- Plasma xanthine oxidoreductase (XOR) activity in patients who require cardiovascular intensive care.Heart and vessels · 2020Article
- Initiating guideline-concordant gout treatment improves arterial endothelial function and reduces intercritical inflammation: a prospective observational study.Arthritis research & therapy · 2020Observational
- Article
- Hyperuricemia and long-term mortality in patients with acute myocardial infarction undergoing percutaneous coronary intervention.Annals of translational medicine · 2019Article
- Dual-Energy Computed Tomography Detection of Cardiovascular Monosodium Urate Deposits in Patients With Gout.JAMA cardiology · 2019Article
- Serum uric acid is an independent predictor of renal outcomes in patients with idiopathic membranous nephropathy.International urology and nephrology · 2019Article
- Impact of gout on in-hospital outcomes of acute coronary syndrome-related hospitalizations and revascularizations: Insights from the national inpatient sample.World journal of cardiology · 2019Article
- [Is There an Effect of Dietary Fructose on Development and Prognosis of Chronic Diseases?]Florence Nightingale hemsirelik dergisi · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 3 countries.
Funding
Abstract
backgroundStudies have suggested a relationship between higher baseline serum uric acid (sUA) levels and an elevated risk of subsequent ischemic cardiovascular outcomes among acute coronary syndrome (ACS) patients; this relationship may be modified by a clinical history of gout and has not been studied in large patient cohorts. We sought to understand the effect of sUA and gout on ACS outcomes.
methodsUsing PLATO and TRACER data on 27,959 ACS patients, we evaluated baseline sUA levels in relation to a composite of cardiovascular death, myocardial infarction (MI), or stroke. We assessed interaction terms to determine if a baseline clinical diagnosis of gout modified this putative relationship; 46% (n=12,882) had sUA levels elevated >6.0 mg/dL.
resultsPatients with elevated levels were more often male with a history of prior MI, diabetes, and heart failure compared with those with sUA <6.0 mg/dL. The unadjusted risk of the composite endpoint increased with corresponding elevations in sUA levels (per 1 mg/dL increase) (HR=1.23 [95% CI: 1.20-1.26]) above the statistical inflection point of 5.0 mg/dL. After adjustment, the association between sUA level and the composite outcome remained significant (HR=1.07 [95% CI: 1.04-1.10]), and baseline gout did not modify this relationship.
conclusionsIn patients with ACS, increasing levels of sUA are associated with an elevated risk of cardiovascular events, regardless of a clinical diagnosis of gout. Further investigation is warranted to determine the mechanism behind this relationship and to delineate whether sUA is an appropriate therapeutic target to reduce cardiovascular risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.